Abstract
Objective
To compare the curative effectiveness of continuous transarterial infusion chemotherapy and systemic venous chemotherapy in treating patients with advanced pancreatic cancer, and to evaluate the value of selective continuous transarterial infusion chemotherapy in treating advanced pancreatic cancer.
Methods
Of the 51 patients with advanced pancreatic cancer receiving chemotherapy with gemcitabine and 5-fluorouracil, 25 patients were treated with selective continuous transarterial infusion chemotherapy, 26 were treated with systemic venous chemotherapy, and curative effectiveness was analyzed retrospectively. Curative effectiveness included tumor volume, clinical benefit response (CBR), acute and subacute toxic reactions of antitumor drugs, survival rate and median survival time.
Results
The objective effective rate in transarterial group was 32.0% versus 23.1% in systemic group without any significant difference (P = 0.475). Clinical benefit rates in transarterial group and systemic group were 80.0% and 50.0% respectively (P = 0.025). The 6-, 9-and 12-month accumulated survival rates and median survival time in transarterial group were higher than those of the systemic group (P = 0.002), the differences were statistically significant. However, the adverse reactions between the two groups were not statistically significant.
Conclusion
Compared with systemic chemotherapy, continuous transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil could improve clinical benefit rate and survival time of patients with advanced pancreatic cancer, it is safe and reliable, and the adverse reactions is less.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Macari M, Giovanniello G, Blair L, et al. Diagnosis of agenesis of the dorsal pancreas with MR pancreatography. AJR Am J Roentgenol, 1998, 170: 144–146.
Homma H, Doi T, Mezawa S, et al. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer, 2000, 89: 303–313.
Zhou JC. Practical tumor medicine. Beijing: People’s Medical Publishing House, 2003. 45–46.
Fu DL, Ni QX, Yu XJ, et al. Regional intra-arterial infusion chemotherapy for pancreatic cancer: an experimental study. Natl Med J Chin (Chinese), 2002, 82: 371–375.
Shi HF, Jin ZY, Zhou ZQ, et al. Transarterial infusion chemotherapy with a combination of gemcitabine and 5-fluorouracil in advanced pancreatic carcinoma. Chin J Radiol (Chinese), 2002, 36: 1072–1074.
Aigner KR, Gailhofer S, Kopp S. Regional versus systemic chemotherapy for advanced pancreatic cancer: a randomized study. Hepatogastroenterology, 1998, 45: 1125–1129.
Hong GB, Zhou JX, Xu LF, et al. Meta-analysis on comparative study of curative effect between interventional therapy and conventional systemic venous chemotherapy in moderate and advanced pancreatic cancer. J Prac Radiol (Chinese), 2004, 20: 350–353.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hong, G., Zhou, J., Luo, J. et al. A clinical study on continuous transarterial infusion chemotherapy and systemic venous chemotherapy with gemcitabine and 5-fluorouracil in treating patients with advanced pancreatic carcinoma. Chinese German J Clin Oncol 6, 457–460 (2007). https://doi.org/10.1007/s10330-007-0086-4
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10330-007-0086-4